Vaccine Safety Registry
RSV Vaccine Safety
Institutional safety information on respiratory syncytial virus (RSV) vaccines. Clinical data for Arexvy and Abrysvo, maternal immunization, and surveillance metadata.
Open Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Respiratory Syncytial Virus (RSV) is a prevalent respiratory pathogen. While typically presenting with mild, upper-respiratory symptoms in healthy adults, it is a primary driver of bronchiolitis and pneumonia in infants and severe lower respiratory tract disease (LRTD) in older adults.
The introduction of high-authority immunization modules in 2023 established a critical clinical defense, significantly reducing the incidence of life-threatening complications and acute hospitalizations within vulnerable cohorts.
Vaccine Formulations
Module specifics & formulations
Formulation Node
Geriatric Protocol (60+)
Approved 2023
- Arexvy - GSK - Recombinant adjuvanted.
- Abrysvo - Pfizer - Bivalent B subunit.
Formulation Node
Maternal Protocol (Gestational)
Abrysvo (Pfizer)
- Administered during weeks 32-36 of gestation to ensure passive neonatal immunity.
Clinical Triage
Eligibility & contraindications
Geriatric Cohort (60+)
- Single-dose seasonal protocol
- Shared clinical decision-making required
- Late summer / early fall administration
Gestational Protocol
- Administer during weeks 32-36
- Window: September through January
- Transfers durable antibodies to infant
Absolute & Relative Contraindications
- Anaphylaxis to previous RSV protocol dose
- Acute moderate-to-severe illness state
- Documented hypersensitivity to module components
Adverse Events
Reported reactions & surveillance
Local Reactions
- Injection site localized pain
- Erythema (Redness)
- Localized induration (Swelling)
Systemic Profile
- Generalized fatigue
- Myalgia (Muscle pain)
- Cephalalgia (Headache)
- Arthralgia (Joint stiffness)
Surveillance Analytics
Post-market surveillance metrics
2023
Registry Launch
60,000+
Trial Subjects
Global
Consensus Profile
Institutional Surveillance
Continuous active monitoring through VAERS and VSD has identified no unexpected clinical concerns. As 2023 modules, ongoing surveillance remains a clinical priority for long-term safety validation.
Editorial Governance
Clinical Reviewers & Authors
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2025Use of Respiratory Syncytial Virus Vaccines in Adults Aged >=60 Years: Updated ACIP Recommendations
MMWR Morbidity and Mortality Weekly Report, 73(29):649-654
- 2WHO2025WHO Preferred Product Characteristics for Respiratory Syncytial Virus Vaccines
World Health Organization Technical Guidance Series
- 3FDA2025AREXVY, ABRYSVO, and BEYFORTUS Approval Packages & Safety Surveillance
U.S. Food and Drug Administration CBER
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Aditya Kumar and clinically reviewed by Dr. Nikhil Chatterjee, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.